What is RFL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RFL?

P/E (TTM) is n/a and 52-week range is $1.08 to $3.96 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RFL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RFL?

The company profile lists revenue (TTM) near $997K, net income (TTM) near -$3.31B, EPS (TTM) near -$0.68 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rafael Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Newark, New Jersey, US, 52.2M shares outstanding, ISIN US75062E1064 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Rafael Holdings Inc

$RFL

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. The company is headquartered in Newark, New Jersey and currently employs 21 full-time employees. The company went IPO on 2018-03-12. The firm's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.

Employees

Website

rafaelholdings.com

IPO

2018-03-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NEW YORK STOCK EXCHANGE, INC.

ISIN

US75062E1064

Headquarters

Newark, New Jersey, US

Shares outstanding

52.2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

7.78%

Browse other companiesFree AI scores and summaries for more stocks